Characteristics of the expression level of MMP-9 and TIMP-1 in hepatocellular and cholangiocellular liver carcinoma
DOI:
https://doi.org/10.14739/2310-1237.2015.1.42819Keywords:
Hepatocellular Carcinoma, Сholangiocellular Carcinoma, Mouse TIMP-1 Protein, Mouse MMP-9 ProteinAbstract
Aim. In order to determine the expression level of immunohistochemical markers of matrix metalloproteinase-9 (ММР-9) and its tissue inhibitor TIMP-1, and area of immunopositive cells а comprehensive histopathological, histological and immunohistochemical study of liver biopsy specimens was carried out in 94 patients, of which 55 (58.51%) patients had hepatocellular carcinoma and 39 (41.49%) – cholangiocellular carcinoma of liver.
Methods and results. In 92.73% of patients with hepatocellular carcinoma and in 89.74% of patients with cholangiocellular carcinoma in malignant cells cytoplasmic expression of MMP-9 was determined. MMP-9 immunopositive cells took 59,33±22,57% of area of the tissue section of hepatocellular carcinoma and 52,71±20,86% of area of the tissue section of cholangiocellular liver cancer. In 80% of hepatocellular carcinoma patients and 74.36% of patients with cholangiocellular carcinoma in tumor cells cytoplasmic expression of TIMP-1 was revealed. TIMP-1 immunopositive cells constituted 21,94±6,27% of area of the tissue section of hepatocellular liver cancer and 33,05±13,85% of area of the tissue section of holangiocellular liver cancer.
Conclusion. In both types of liver cancer direct strong relationship was noted between high levels of expression of MMP-9 by the tumor cells and low expression of TIMP-1, which indicates high invasive potential and aggressiveness of hepatocellular carcinoma and cholangiocellular carcinoma.
References
Malemud, C. J. (2006) Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci, 11, 1696–1701. doi: 10.2741/1915.
Visse, R., & Nagase, H. (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res, 92(8), 827–839. doi: 10.1161/01.RES.0000070112.80711.3D.
Joo, Y-E, Seo, Y-H, Lee, W-S, Kim, H-S, Choi, S-K, Rew, J-S, et al. (2000) Expression of Tissue Inhibitors of Metalloproteinases (TIMPs) in Hepatocellular Carcinoma. Korean J Intern Med., 15(3), 171–178.
French, J. J., Midwinter, M. J., Bennet, M. K., Manas, D. M., & Charley, R. M. (2005) A matrix metalloproteinase inhibitor to treat unresectable cholangiocarcinoma. HPB (Oxford), 7(4), 289–291. doi: 10.1080/13651820510042246.
Theret, N., Musso, O., Turlin, B., Lotrian, D., Bioulac-Sage, P., Campion, J.P., et al. (2001) Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas. Hepatology, 34(1), 82–88.
Ip, Y. C., Cheung, S. T., Leung, K. L., Fan, S. T. (2005) Mechanism of metastasis by membrane type 1-matrix metalloproteinase in hepatocellular carcinoma. World J Gastroenterol, 11(40), 6269–6276. doi: 10.3748/wjg.v11.i40.6269.
Gao, Z. H., Tretiakova, M. S., Liu, W. H., Gong, C., Farris, P. D., & Hart, J. (2006) Association of E-cadherin, matrix metalloproteinases, and tissue inhibitors of metalloproteinases with the progression and metastasis of hepatocellular carcinoma. Mod Pathol., 19(4), 533–540.
Jan, YY., Yeh, TS., Yeh, JN., Yang, HR., & Chen, MF. (2004) Expression of Epidermal Growth Factor Receptor, Apomucins, Matrix Metalloproteinases, and p53 in Rat and Human Cholangiocarcinoma. Ann Surg, 240(1), 89–94. doi: 10.1097/01.sla.0000129492.95311.f2.
Kim, H. J., Kim, J. S., Kang, C. D., Lee, S. J., Kim, J. Y., Yeon, J. E., et al. (2005). Expression of epidermal growth factor receptor, ErbB2 and matrix metalloproteinase-9 in hepatolithiasis and cholangiocarcinoma. Korean J Gastroenterol., 45(1), 52–59.
Rasband, W. S. & Image J. U. S. National Institutes of Health, Bethesda, Maryland, USA Retrieved from http://imagej.nih.gov/ij/, 1997–2012.
Ishii, Y., Nakasato, Y., Kobayashi, S., Yamazaki, Y., & Aoki, T. (2003) A Study on Angiogenesis-Related Matrix Metalloproteinase Networks in Primary Hepatocellular Carcinoma. J. Exp. Clin. Cancer Res., 22(3), 461–470.
Yan, Zhang, Yucheng, Shen, Bin, Cao, Aiting, Yan, & Haoming, Ji (2015) Elevated expression levels of androgen receptors and matrix metalloproteinase-2 and -9 in 30 cases of hepatocellular carcinoma compared with adjacent tissues as predictors of cancer invasion and staging. Experimental and therapeutic medicine, 9(3), 905–908.
Nart, D., Yaman, B., Yılmaz, F., Zeytunlu, M., Karasu, Z., Kılıc, M. (2010) Expression of matrix metalloproteinase-9 in predicting prognosis of hepatocellular carcinoma after liver transplantation. J Liver Transplantation, 16(5), 621–630. doi: 10.1002/lt.22028.
McKenna, G. J., Chen, Y., Smith, R. M., Meneghetti, A., Ong, C., McMaster, R. et al. (2002) A role for matrix metalloproteinases and tumor host interaction in hepatocellular carcinomas. Am J Surg., 183(5), 588–594. doi: 10.1016/S0002-9610(02)00833-4.
Jiang, Y. F., Yang, Z. H., Hu, J. Q. (2000) Recurrence or metastasis of HCC: predictors, early detection and experimental antiangiogenic therapy. World J Gastroenterol, 6(1), 61–65.
Roeb, E., Bosserhoff, A.K., Hamacher, S., Jansen, B., Dahmen, J., Wagner, S. et al. (2005) Enhanced migration of tissue inhibitor of metalloproteinase overexpressing hepatoma cells is attributed to gelatinases: relevance to intracellular signaling pathways. World J Gastroenterol, 11, 1096–1104. doi: 10.3748/wjg.v11.i8.1096.
Matsumoto, E., Nakatsukasa, H., Nouso, K., Kobayashi, Y., Nakamura, S., Suzuki, M., et al. (2004) Increased levels of tissue inhibitor of metalloproteinase-1 in human hepatocellular carcinoma. Liver Int., 24(4), 379–383. doi: 10.1111/j.1478-3231.2004.0923.x.
Kutikhin, A. G., Natcheva, L. V., Magarill, Yu. A. (2009) Prognosticheskaya rol' i molekulyarno-biologicheskie aspekty formirovaniya kapsuly gepatocellyulyarnoj karcinomy: obzor literatury [Prognostic role and molecular-biological aspects of hcc capsule formation: review]. Sibirskij onkologicheskij zhurnal, 6(36), 70–77. [in Russian].
Joo, Y. E., Seo, Y. H., Lee, W. S., Kim, H. S., Choi, S.K., Rew, J.S., et al. (2000) Expression of Tissue Inhibitors of Metalloproteinases (TIMPs) in Hepatocellular Carcinoma. Korean J Intern Med, 15(3), 171–178.
Sawada, S., Murakami, K., Murata, J., Tsukada, K., & Saiki, I. (2001) Accumulation of extracellular matrix in the liver induces high metastatic potential of hepatocellular carcinoma to the lung. Int J Oncol, 19(1), 65–70. doi: 10.3892/ijo.19.1.65.
Shirabe, K., Shimada, M., Kajiyama, K., Hasegawa, H., Gion, T., Ikeda, Y., et al. (1999) Expression of matrix metalloproteinase-9 in surgically resected intrahepatic cholangiocarcinoma. Surgery, 126(5), 842–846.
Itatsu, K., Zen, Y., Yamaguchi, J., Ohira, S., Ishikawa, A., Ikeda, H., et al. (2008) Expression of matrix metalloproteinase 7 is an unfavorable postoperative prognostic factor in cholangiocarcinoma of the perihilar, hilar, and extrahepatic bile ducts. Hum Pathol, 39(5), 710–719. doi: 10.1016/j.humpath.2007.09.016.
Qi, Sun, Chuanzong, Zhao1, Leizhou, Xia , Zhaobin, He , Zhihua, Lu , Chuan, Liu, et al. (2014) High expression of matrix metalloproteinase-9 indicates poor prognosis in human hilar cholangiocarcinoma. Int J Clin Exp Pathol, 7(9), 6157–6164.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
